Transcranial Magnetic Stimulation for Apathy in Mild Cognitive Impairment
Key facts
- Who runs it
- VA Office of Research and Development
- Where
- Little Rock, United StatesSee the site
- Trial code
- Status
- Completed
- People taking part
- 103 people enrolled
- Started
- 1 Nov 2018
- Ended
- 31 Oct 2024
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Transcranial Magnetic Stimulation
- Record updated
- 22 May 2026
Who can take part
- Age
- 55 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 30 criteriaShow less
Who can take part
- meeting the modified Mayo Clinic criteria for MCI
- Having caregivers
- apathy threshold (NPI)
- MMSE 23
- On stable dose of antidepressants for at least a month (if applicable)
Who cannot take part
- Taking ototoxic medications: Aminoglycosides, Cisplatin
- Renal disease requiring dialysis
- Metastatic cancer or undergoing chemotherapy
- Deep venous thrombosis or myocardial infarction in past 3 months
- Uncontrolled malignant cardiac arrhythmia
- Unstable angina in past month
- End-stage congestive heart failure; EXCLUSIONARY DUE TO rTMS: ALL PHASE II AND SUBSET OF PHASE I THAT RECEIVE SINGLE SESSION rTMS
- Taking medications known to increase risk of seizures from 2012 Beers criteria such as bupropion, chlorpromazine, clozapine
- Taking other medications known to increase risk of seizures such as tricyclic antidepressants
- History of seizures/ seizures in first degree relatives
- History of stroke, aneurysm, or cranial neurosurgery
- History of bipolar disorder
- Current alcohol related disorder needing medical treatment
- History of Tourette's syndrome or presence of motor tics
- History of abnormal electroencephalogram (EEG); EXCLUSIONARY DUE TO CONFOUNDING WITH APATHY: PHASE II
- Current episode of Major Depressive Disorder
- Change in dose of dementia medications within 30 days
- Uncontrolled diabetes mellitus (Fasting BS>200mg/dl, HbA1c>10)
- PHASE I
- Uncontrolled blood pressure (>160/100, <100 systolic)
- Cerebral aneurysm or intracranial bleed in past year
- Unstable abdominal or thoracic aortic aneurysm (>4cm)
- Those with implanted device
- Current use of stimulants
- Change in dose of antidepressants within 30 days
Where in United States
- Central Arkansas Veterans Healthcare System, Little Rock, ARLittle Rock, United States
About the trial
What the trial wants to find out
Apathy, a profound loss of initiative and motivation, is often seen in older Veterans with memory problems. Apathy leads to serious health problems, increases dependency, and caregiver burden. If untreated, apathy hastens the progression to frank dementia. In a pilot study, the investigators found that apathy, working memory, and function can be restored using magnetic stimulation in some but not all older Veterans. The reason for this variation is unknown. The investigators propose a three-phase study in 125 older Veterans with mild memory problems. Their motivation, memory, and function will be measured periodically. Veterans with apathy that are eligible for treatment will receive either real or sham magnetic stimulation to the front part of their brain over 20 sessions. Genetic testing and biomarkers will be used to differentiate those who respond to magnetic stimulation from those who do not. Impact on function, quality of life, and rates of progression to dementia will also be studied.
Read full original descriptionShow less
A project modification was obtained to conduct a cross-sectional study, the COVID Dementia study. The cross-sectional study will examine the effect of the pandemic on MCI and AD patients and their caregivers ("individual COVID-related factors" such as, personally infected, death of a friend/family member, economic hardship, disruption in care, isolation), barriers to telehealth, caregiver distress, NPS, cognition (including onset of delirium), and function. Our goal is to develop a multi-pronged, remotely deliverable intervention to address consequences of healthcare disruptions in older Veterans with cognitive impairment.
Aim 1. To explore the association between COVID-related factors and neuropsychiatric symptoms in individuals with MCI and AD. Hypothesis: The number of COVID-related factors endorsed by caregivers will be positively correlated with the severity of NPI-Q in individuals with MCI and AD.
Aim 2. To assess cognition (telephonic version of the Montreal Cognitive Assessment; tMoCA12, and daily function (Functional Activities Questionnaire; FAQ13). Hypothesis: The number of COVID-related factors will be positively correlated with the severity of cognitive and functional deficits in individuals with MCI and AD.
Aim 3. To explore the associations among COVID-related factors and caregiver distress. Hypothesis: Caregiver resilience and perceived social support will modify the association between COVID-related factors and severity of distress in caregivers.
The 3 groups in the trial
- Apathy +, rTMS -No study treatment, for comparison
This arm will be followed without intervention
- rTMSExisting treatment, for comparison
This group will be randomized to receive rTMS treatment
Treatment: Transcranial Magnetic Stimulation
- ShamSham treatment, for comparison
This group will be randomized to receive sham treatment
Treatment: Transcranial Magnetic Stimulation
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 22 May 2026